$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing
By Mark Zipkin, Staff Writer | Apr 15, 2019 | 8:46 PM GMT
The 6x multiple Catalent is paying for gene therapy manufacturer Paragon Bioservices suggests buyers believe gene therapy companies will remain heavily dependent on outsourcing as new therapies are approved in the next few years.
Read the full 354 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD